logo
Plus   Neg
Share
Email

MacroGenics Shares Surge On Positive Margetuximab Data

MacroGenics, Inc. (MGNX) announced positive results from SOPHIA, the company's Phase 3 clinical study of margetuximab in HER2-positive metastatic breast cancer patients. MacroGenics anticipates submitting a Biologics License Application (BLA) to the U.S. Food and Drug Administration in the second half of 2019.

In Wednesday pre-market trade, MGNX is trading at $23.52, up $12.41 or 111.70 percent.

Margetuximab is an investigational immune-enhancing monoclonal antibody derived from the Company's proprietary Fc Optimization technology platform. The SOPHIA clinical trial met the primary endpoint of prolongation of progression-free survival or PFS in patients treated with the combination of margetuximab plus chemotherapy compared to trastuzumab plus chemotherapy. Patients in the margetuximab arm experienced a 24% risk reduction in PFS compared to patients in the trastuzumab arm (HR=0.76, p=0.033).

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Apple is tracking iPhones that were stolen from its retail stores in recent days during the civil unrest, according to reports citing a warning message popping up on the stolen iPhones. Four current and former senior executives from two major broiler chicken producers, including Pilgrim's Pride CEO Jayson Penn, have been indicted for price fixing. Kezar Life Sciences, Inc. (KZR) - Shares of the clinical-stage biotechnology company soared nearly 80% after closing bell. The company's lead drug candidate is KZR-616, a selective inhibitor of immunoproteasome that plays a crucial role in the immune system. KZR-616 is under a phase Ib/II study in...
Follow RTT